David Alan Campbell serves as Executive at Janux Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, David Alan Campbell has executed 6 insider transactions totaling $1.3M, demonstrating a bearish approach to their equity position. Their most recent transaction on Jan 2, 2026 involved receiving (via award) 338,100 shares valued at $0.
David Alan Campbell currently holds 338,100 shares of Janux Therapeutics, Inc. (JANX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, David Alan Campbell has been a net seller of JANX stock. They have purchased $0 and sold $1.3M worth of shares.
David Alan Campbell's most recent insider trade was on Jan 2, 2026, when they sold 338,100 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Jan 2, 2026 | JANX | $110.8K | Sale | 8,072 | $13.73 | Discretionary |
| Sep 27, 2024 | JANX | $38.0K | Sale | 795 | $47.84 | Planned |
| Sep 27, 2024 | JANX | $245.9K | Sale | 5,248 | $46.86 | Planned |
| Sep 27, 2024 | JANX | $873.7K | Sale | 18,957 | $46.09 | Planned |